Evaluation of Intravenous Infusion Port Abdominal Wall Implantation Technology for Delivery of Intraperitoneal Chemotherapy in Advanced-Stage Ovarian Cancer

This study evaluated the safety and efficacy of a novel intravenous infusion port abdominal wall implantation technique for intraperitoneal chemotherapy in advanced-stage ovarian cancer (FIGO III-IV). In a single-arm clinical trial of 42 patients, the implantation success rate reached 100%, with 97.6% of patients completing at least four treatment cycles. The overall response rate (CR+PR) was 69.0%. Common complications included puncture site pain (95.2%), abdominal distension (42.9%), and lumen blockage (14.3%), all of which were mild and manageable. Both physician and patient satisfaction scores exceeded 91 points. The technique eliminated the need for laparotomy, minimized trauma, simplified procedures, and ensured long-term safety, making it particularly suitable for peritoneal metastasis and pelvic recurrence. Limitations included the small sample size and lack of a control group, warranting future multicenter validation. This approach provides a feasible option for intraperitoneal chemotherapy in primary care settings, potentially optimizing treatment strategies for advanced ovarian cancer.